GWM Advisors LLC raised its position in Novartis AG (NYSE:NVS) by 10.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,081 shares of the company’s stock after buying an additional 939 shares during the quarter. GWM Advisors LLC’s holdings in Novartis were worth $969,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in NVS. BlackRock Inc. raised its position in shares of Novartis by 223.5% in the 4th quarter. BlackRock Inc. now owns 11,439,298 shares of the company’s stock worth $981,607,000 after acquiring an additional 7,902,964 shares in the last quarter. FMR LLC raised its holdings in Novartis by 441.6% in the 4th quarter. FMR LLC now owns 7,016,047 shares of the company’s stock worth $602,046,000 after purchasing an additional 5,720,650 shares during the period. Lazard Asset Management LLC raised its holdings in Novartis by 407.4% in the 1st quarter. Lazard Asset Management LLC now owns 2,525,897 shares of the company’s stock worth $242,839,000 after purchasing an additional 2,028,045 shares during the period. Bank of America Corp DE raised its holdings in Novartis by 25.1% in the 4th quarter. Bank of America Corp DE now owns 9,053,828 shares of the company’s stock worth $776,909,000 after purchasing an additional 1,817,005 shares during the period. Finally, Mawer Investment Management Ltd. raised its holdings in Novartis by 53.4% in the 4th quarter. Mawer Investment Management Ltd. now owns 4,764,486 shares of the company’s stock worth $408,841,000 after purchasing an additional 1,658,037 shares during the period. Institutional investors own 11.81% of the company’s stock.
NYSE:NVS opened at $89.77 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.83 and a debt-to-equity ratio of 0.48. The stock has a market cap of $207.37 billion, a price-to-earnings ratio of 17.64, a price-to-earnings-growth ratio of 2.13 and a beta of 0.56. Novartis AG has a 52 week low of $63.60 and a 52 week high of $90.21.
A number of equities analysts recently commented on NVS shares. Morgan Stanley cut Novartis from an “equal weight” rating to an “underweight” rating and raised their target price for the stock from $82.50 to $82.52 in a report on Wednesday, April 10th. Zacks Investment Research cut Novartis from a “hold” rating to a “strong sell” rating in a report on Thursday, April 11th. Guggenheim raised Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price target on the stock in a report on Wednesday, April 24th. Finally, Liberum Capital raised Novartis from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Five research analysts have rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Novartis has an average rating of “Hold” and a consensus target price of $87.57.
ILLEGAL ACTIVITY WARNING: “Novartis AG (NYSE:NVS) Shares Bought by GWM Advisors LLC” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/4371427/novartis-ag-nysenvs-shares-bought-by-gwm-advisors-llc.html.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Further Reading: What does a bar chart display?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.